KRAS and cancer: Taken together, this is the first report showing that Prima-1 overcomes the resistance to 3-BrPA in hypoxic wt p53 KRAS-mutant cells [8, 28, 33, 60] by promoting wt p53 reactivation [61] and pro-oxidant cancer therapeutics [9, 12, 62].